A phase I trial of MIN 301 for the treatment of Parkinson's disease

Trial Profile

A phase I trial of MIN 301 for the treatment of Parkinson's disease

Planning
Phase of Trial: Phase I

Latest Information Update: 26 May 2015

At a glance

  • Drugs MIN 301 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 26 May 2015 New trial record
    • 26 Mar 2015 According to a company media release, Minerva Neurosciences plans to file an Investigational New Drug (IND) application in 2016 and initiate this study following its acceptance.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top